Association of body mass index and long-term mortality in patients from nationwide LIPIDOGRAM 2004-2015 cohort studies: no obesity paradox?


Journal

Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637

Informations de publication

Date de publication:
28 Nov 2023
Historique:
received: 13 09 2023
accepted: 08 11 2023
medline: 30 11 2023
pubmed: 29 11 2023
entrez: 29 11 2023
Statut: epublish

Résumé

An obesity paradox has been described in relation to adverse clinical outcomes (e.g., mortality) with lower body mass index (BMI). We sought to evaluate the association between BMI and weight loss with long-term all-cause mortality in adult populations under the care of family physicians. LIPIDOGRAM studies were conducted in primary care in Poland in 2004, 2006, and 2015 and enrolled a total of 45,615 patients. The LIPIDOGRAM Plus study included 1627 patients recruited in the LIPIDOGRAM 2004 and repeated measurements in 2006 edition. Patients were classified by BMI categories as underweight, normal weight, overweight and class I, II, or III (obesity). Follow-up data up to December 2021 were obtained from the Central Statistical Office. Differences in all-cause mortality were analyzed using Kaplan‒Meier and Cox regression analyses. Of 45,615 patients, 10,987 (24.1%) were normal weight, 320 (0.7%) were underweight, 19,134 (41.9%) were overweight, and 15,174 (33.2%) lived with obesity. Follow-up was available for 44,620 patients (97.8%, median duration 15.3 years, 61.7% females). In the crude analysis, long-term all-cause mortality was lowest for the normal-weight group (14%) compared with other categories. After adjusting for comorbidities, the highest risk of death was observed for the class III obesity and underweight categories (hazard ratio, HR 1.79, 95% CI [1.55-2.05] and HR 1.57, 95% CI [1.22-2.04]), respectively. The LIPIDOGRAM Plus analysis revealed that a decrease in body weight (by 5 and 10%) over 2 years was associated with a significantly increased risk of death during long-term follow-up-HR 1.45 (95% CI 1.05-2.02, p = 0.03) and HR 1.67 (95% CI 1.02-2.74, p < 0.001). Patients who experienced weight loss were older and more burdened with comorbidities. Being underweight, overweight or obese is associated with a higher mortality risk in a population of patients in primary care. Patients who lost weight were older and more burdened with cardiometabolic diseases, which may suggest unintentional weight loss, and were at higher risk of death in the long-term follow-up. In nonsmoking patients without comorbidities, the lowest mortality was observed in those with a BMI < 25 kg/m

Sections du résumé

BACKGROUND BACKGROUND
An obesity paradox has been described in relation to adverse clinical outcomes (e.g., mortality) with lower body mass index (BMI).
AIMS OBJECTIVE
We sought to evaluate the association between BMI and weight loss with long-term all-cause mortality in adult populations under the care of family physicians.
METHODS METHODS
LIPIDOGRAM studies were conducted in primary care in Poland in 2004, 2006, and 2015 and enrolled a total of 45,615 patients. The LIPIDOGRAM Plus study included 1627 patients recruited in the LIPIDOGRAM 2004 and repeated measurements in 2006 edition. Patients were classified by BMI categories as underweight, normal weight, overweight and class I, II, or III (obesity). Follow-up data up to December 2021 were obtained from the Central Statistical Office. Differences in all-cause mortality were analyzed using Kaplan‒Meier and Cox regression analyses.
RESULTS RESULTS
Of 45,615 patients, 10,987 (24.1%) were normal weight, 320 (0.7%) were underweight, 19,134 (41.9%) were overweight, and 15,174 (33.2%) lived with obesity. Follow-up was available for 44,620 patients (97.8%, median duration 15.3 years, 61.7% females). In the crude analysis, long-term all-cause mortality was lowest for the normal-weight group (14%) compared with other categories. After adjusting for comorbidities, the highest risk of death was observed for the class III obesity and underweight categories (hazard ratio, HR 1.79, 95% CI [1.55-2.05] and HR 1.57, 95% CI [1.22-2.04]), respectively. The LIPIDOGRAM Plus analysis revealed that a decrease in body weight (by 5 and 10%) over 2 years was associated with a significantly increased risk of death during long-term follow-up-HR 1.45 (95% CI 1.05-2.02, p = 0.03) and HR 1.67 (95% CI 1.02-2.74, p < 0.001). Patients who experienced weight loss were older and more burdened with comorbidities.
CONCLUSIONS CONCLUSIONS
Being underweight, overweight or obese is associated with a higher mortality risk in a population of patients in primary care. Patients who lost weight were older and more burdened with cardiometabolic diseases, which may suggest unintentional weight loss, and were at higher risk of death in the long-term follow-up. In nonsmoking patients without comorbidities, the lowest mortality was observed in those with a BMI < 25 kg/m

Identifiants

pubmed: 38017465
doi: 10.1186/s12933-023-02059-0
pii: 10.1186/s12933-023-02059-0
pmc: PMC10685602
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

323

Informations de copyright

© 2023. The Author(s).

Références

Int J Cardiol. 2023 Jun 1;380:48-55
pubmed: 36940822
BMJ Open. 2019 Dec 15;9(12):e028638
pubmed: 31843818
Arch Med Sci. 2020 Jun 04;18(3):604-616
pubmed: 35591817
Eur J Epidemiol. 2014 Nov;29(11):801-12
pubmed: 25354991
BMJ. 2016 Apr 12;353:i1246
pubmed: 27071971
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Int J Obes (Lond). 2017 Aug;41(8):1162-1163
pubmed: 28584251
Epidemiology. 2016 Jul;27(4):525-30
pubmed: 27075676
Diabetes Obes Metab. 2022 Aug;24(8):1553-1564
pubmed: 35441470
PLoS One. 2015 Apr 17;10(4):e0123579
pubmed: 25886648
BMJ. 2016 Nov 24;355:i5855
pubmed: 27884868
Ann Med. 2016 Dec;48(8):603-613
pubmed: 27427379
Gerontology. 2014;60(4):294-305
pubmed: 24731978
Eur J Prev Cardiol. 2023 Sep 6;30(12):1195-1204
pubmed: 37039119
JAMA. 2016 May 10;315(18):1989-96
pubmed: 27163987
Curr Obes Rep. 2017 Jun;6(2):187-194
pubmed: 28455679
Cardiovasc Diabetol. 2022 Dec 2;21(1):266
pubmed: 36461034
Obes Rev. 2007 Jan;8(1):41-59
pubmed: 17212795
J Am Coll Cardiol. 2019 Apr 2;73(12):1430-1443
pubmed: 30922474
Curr Nutr Rep. 2019 Sep;8(3):175-181
pubmed: 31129887
Int J Epidemiol. 2009 Oct;38(5):1175-91
pubmed: 19773415
ESC Heart Fail. 2017 Nov;4(4):492-498
pubmed: 29154428
Obesity (Silver Spring). 2006 May;14(5):737-52
pubmed: 16855180
Diabet Med. 1999 May;16(5):442-3
pubmed: 10342346
Eat Weight Disord. 2021 May;26(4):1057-1068
pubmed: 32954485
PLoS One. 2016 Mar 23;11(3):e0148926
pubmed: 27007232
Eur J Heart Fail. 2018 Nov;20(11):1580-1587
pubmed: 30160804
Heart. 2009 Mar;95(6):454-60
pubmed: 18697804
Clin Res Cardiol. 2021 Aug;110(8):1280-1291
pubmed: 33704552
Lancet. 2006 Aug 19;368(9536):666-78
pubmed: 16920472
N Engl J Med. 2008 Jun 12;358(24):2545-59
pubmed: 18539917
Cancer Res. 1984 Dec;44(12 Pt 1):5940-58
pubmed: 6388830
Can Fam Physician. 2012 May;58(5):517-23
pubmed: 22586192
Prog Cardiovasc Dis. 2018 Jul - Aug;61(2):151-156
pubmed: 29852198
Nutr Res Rev. 2009 Jun;22(1):93-108
pubmed: 19555520
Atherosclerosis. 2004 Apr;173(2):381-91
pubmed: 15195638
JAMA. 2003 May 21;289(19):2560-72
pubmed: 12748199
PLoS Med. 2005 Jun;2(6):e171
pubmed: 15971946
Am J Med. 2013 Jul;126(7):640.e9-17
pubmed: 23601271
Cardiovasc Diabetol. 2022 May 16;21(1):78
pubmed: 35578337
N Engl J Med. 1990 Mar 29;322(13):882-9
pubmed: 2314422
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
J Am Coll Cardiol. 2014 Apr 15;63(14):1345-54
pubmed: 24530666
Eur Heart J. 2013 Oct;34(39):3035-87
pubmed: 23996285
BMJ. 2007 Dec 1;335(7630):1134
pubmed: 17986716
N Engl J Med. 2002 Aug 1;347(5):305-13
pubmed: 12151467
Addict Behav. 1998 Sep-Oct;23(5):609-22
pubmed: 9768298
PLoS One. 2014 Jan 31;9(1):e86837
pubmed: 24497983
JAMA. 2009 Apr 8;301(14):1439-50
pubmed: 19351941
J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1477-1486
pubmed: 35352504
Lancet. 2017 Dec 16;390(10113):2627-2642
pubmed: 29029897
Lancet. 2009 Mar 28;373(9669):1083-96
pubmed: 19299006

Auteurs

Tadeusz Osadnik (T)

Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Jordana 38 St., 41-808, Zabrze, Poland.
Cardiology and Lipid Disorders Clinic, Independent Public Health Care Institution "REPTY" Upper Silesian Rehabilitation Centre, ul. Śniadeckiego 1, 42-600, Tarnowskie Góry, Poland.

Dariusz Nowak (D)

Municipal Hospital, ul. Mirowska 15, 42-202, Czestochowa, Poland.

Kamila Osadnik (K)

Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.

Marek Gierlotka (M)

Department of Cardiology, Institute of Medical Sciences, University of Opole, Al. W. Witosa 26, 45-401, Opole, Poland.

Adam Windak (A)

Department of Family Medicine, Jagiellonian University Medical College, Bochenska 4 Street, 31-061, Kraków, Poland.

Tomasz Tomasik (T)

Department of Family Medicine, Jagiellonian University Medical College, Bochenska 4 Street, 31-061, Kraków, Poland.

Mirosław Mastej (M)

Mastej Medical Center, Staszica 17A St., 38-200, Jasło, Poland.

Beata Łabuz-Roszak (B)

Department of Neurology, Institute of Medical Sciences, University of Opole, Oleska 48 St., 45-052, Opole, Poland.

Kacper Jóźwiak (K)

Faculty of Health Sciences, Jagiellonian University Collegium Medicum, ul/Street: Piotra Michałowskiego 12, 31-126, Kraków, Poland.

Gregory Y H Lip (GYH)

Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, UK.
Liverpool Centre for Cardiovascular Science, Liverpool John Moores University, Liverpool, UK.
Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, Liverpool, UK.
Danish Center for Clinical Health Services Research, Department of Clinical Medicine, Aalborg University, 9220, Åalborg, Denmark.

Dimitri P Mikhailidis (DP)

Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London (UCL), Pond St., London, NW3 2QG, UK.

Peter P Toth (PP)

Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Department of Preventive Cardiology, CGH Medical Center, 101 East Miller Road, Sterling, IL, 61081, USA.

Naveed Sattar (N)

Institute of Cardiovascular and Medical Science, University of Glasgow, University Place, Glasgow, G12 8TA, UK.

Marcin Goławski (M)

Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.

Jacek Jóźwiak (J)

Department of Family Medicine and Public Health, University of Opole, Oleska 48 St., 45-052, Opole, Poland.

Maciej Banach (M)

Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. maciej.banach@umed.lodz.pl.
Department of Cardiology and Adult Congenital Heart Diseases, Polish Mother's Memorial Hospital Research Institute (PMMHRI), Rzgowska 281/289, 93-338, Lodz, Poland. maciej.banach@umed.lodz.pl.
Cardiovascular Research Centre, University of Zielona Gora, ul. Zyty 28, 65-046, Zielona Gora, Poland. maciej.banach@umed.lodz.pl.
Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Rzgowska 281/289, 93-338, Lodz, Poland. maciej.banach@umed.lodz.pl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH